Abstract
Regenerative medicine is a subdivision of medicine that improves methods to regrow, repair or replace unhealthy cells and tissues to return to normal function. Cell therapy, gene therapy, nanomedicine as choices used to cure neurodegenerative disease. Recently, studies related to the treatment of neurodegenerative disorders have been focused on stem cell therapy and Nano-drugs beyond other than regenerative medicine. Hence, by data from experimental models and clinical trials, we review the impact of stem cell therapy, gene therapy, and nanomedicine on the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic lateral sclerosis (ALS). Indeed, improved knowledge and continued research on gene therapy and nanomedicine in treating Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis lead to advancements in effective and practical treatments for neurodegenerative diseases.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- PD:
-
Parkinson’s disease
- ALS:
-
Amyotrophic lateral sclerosis
- BDNF:
-
Brain-derived neurotrophic factor
- NGF:
-
Nerve growth factor
- DA:
-
Dopaminergic neuron
- NSCs:
-
Neural stem cells
- ESCs:
-
Embryonic stem cells
- VEGF:
-
Vascular endothelial cell growth factor
- AAV:
-
Adeno-associated virus
References
Aderibigbe BA (2017) Metal-based nanoparticles for the treatment of infectious diseases. Molecules 22(8):1370
Alam M, Abbas K (2021) An insight into neurodegenerative disorders, their therapeutic approaches and drugs available for tackling with neurodegeneration: a review. IAR J Med Case Rep 2(3):1
Alipour M et al (2019) Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks. Mol Biol Rep 46(1):1425–1446
Alves S et al (2017) Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice. Brain 140(3):826–842
Amini N et al (2016) Efficacy of human adipose tissue-derived stem cells on neonatal bilirubin encephalopathy in rats. Neurotox Res 29(4):514–524
Amini N et al (2019) Transplantation of adipose tissue-derived stem cells into brain through cerebrospinal fluid in rat models: protocol development and initial outcome data. Curr Stem Cell Res Ther 14(2):191–195
Atala A (2004) Tissue engineering and regenerative medicine: concepts for clinical application. Rejuvenation Res 7(1):15–31
Azzouz M et al (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429(6990):413–417
Babahajian A et al (2019) Neuroprotective effects of trolox, human chorionic gonadotropin, and carnosic acid on hippocampal neurodegeneration after ischemia-reperfusion injury. Curr Stem Cell Res Ther 14(2):177–183
Bangde P et al (2017) Potential gene therapy towards treating neurodegenerative disea ses employing polymeric nanosystems. Curr Gene Ther 17(2):170–183
Biferi MG et al (2017) A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol Ther 25(9):2038–2052
Björklund A, Lindvall O (2000) Cell replacement therapies for central nervous system disorders. Nat Neurosci 3(6):537–544
Brooks BR et al (2000) El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
Chen T et al (2017) Small-sized mPEG–PLGA nanoparticles of schisantherin a with sustained release for enhanced brain uptake and anti-parkinsonian activity. ACS Appl Mater Interfaces 9(11):9516–9527
Chen W et al (2018) Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater 30(3):1703458
Chowdhury SR et al (2016) Modulation of amyloid aggregates into nontoxic coaggregates by hydroxyquinoline appended polyfluorene. ACS Appl Mater Interface 8(21):13309–13319
Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 35:441–468
Cornejo F, von Bernhardi R (2016) Age-dependent changes in the activation and regulation of microglia. Gl Cell Health Disease CNS. 1:205
Cummings J, Fox N (2017) Defining disease modifying therapy for Alzheimer’s disease. J Prev Alzheimers Dis 4(2):109–115
Cummings J et al (2017) Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s Dement Trans Res Clin Interv 3(3):367–384
Dong X (2018) Current strategies for brain drug delivery. Theranostics 8(6):1481–1493
El Andaloussi S et al (2013) Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 65(3):391–397
Emborg M et al (2009) Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 36(2):303–311
Enciu AM et al (2011) Neuroregeneration in neurodegenerative disorders. BMC Neurol 11(1):1–7
Garbuzova-Davis S et al (2002) Positive effect of transplantation of hNT neurons (NTera 2/D1 Cell-Line) in a model of familial amyotrophic lateral sclerosis-volume 174, number 2 (2002) pages 169-180. Exp Neurol 2(175):451
Hagell P et al (1999) Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft. Brain 122(6):1121–1132
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
Harper JM et al (2004) Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci 101(18):7123–7128
Herzog CD et al (2013) Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 58:38–48
Hunsberger JG et al (2016) Accelerating stem cell trials for Alzheimer’s disease. Lancet Neurol 15(2):219–230
Hwang D et al (2009) Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther 16(10):1234–1244
Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat 4(4):743–757
Kerr DA et al (2003) Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 23(12):5131–5140
Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942–955
Kim SU, De Vellis J (2009) Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 87(10):2183–2200
Kiyota T et al (2015) AAV2/1 CD74 gene transfer reduces β-amyloidosis and improves learning and memory in a mouse model of Alzheimer’s disease. Mol Ther 23(11):1712–1721
Kojima R et al (2018) Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun 9(1):1305
Korecka JA et al (2017) Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson’s disease. J Neurosci 37(39):9361–9379
Kotterman MA, Chalberg TW, Schaffer DV (2015) Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17:63–89
Lee HJ et al (2007) Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2(1):e156
LeWitt PA, Giladi N, Navon N (2019) Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson’s disease. Parkinsonism Relat Disord 65:131–138
Li D et al (2017) Slow intrathecal injection of rAAVrh10 enhances its transduction of spinal cord and therapeutic efficacy in a mutant SOD1 model of ALS. Neuroscience 365:192–205
Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders—time for clinical translation? J Clin Investig 120(1):29–40
Maney V, Singh M (2017) An in vitro assessment of novel chitosan/bimetallic PtAu nanocomposites as delivery vehicles for doxorubicin. Nanomedicine 12(21):2625–2640
Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340(25):1970–1980
Mazibuko Z et al (2015) A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. J Pharm Sci 104(4):1213–1229
Miles GB et al (2004) Functional properties of motoneurons derived from mouse embryonic stem cells. J Neurosci 24(36):7848–7858
Morizane A (2019) Cell therapy for Parkinson’s disease with induced pluripotent stem cells. Rinsho Shinkeigaku Clin Neurol 59(3):119–124
Murlidharan G, Samulski RJ, Asokan A (2014) Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci 7:76
O’Connor DM, Boulis NM (2015) Gene therapy for neurodegenerative diseases. Trends Mol Med 21(8):504–512
Onyango IG (2018) Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer’s disease. Neural Regen Res 13(1):19
Ortolano S, Spuch C, Navarro C (2012) Present and future of adeno associated virus based gene therapy approaches. Recent Pat Endocr Metab Immune Drug Discove 6(1):47–66
Pahuja R et al (2015) Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 9(5):4850–4871
Piguet F, Alves S, Cartier N (2017) Clinical gene therapy for neurodegenerative diseases: past, present, and future. Hum Gene Ther 28(11):988–1003
Pillay S et al (2016) An essential receptor for adeno-associated virus infection. Nature 530(7588):108–112
Pisati F et al (2007) Induction of neurotrophin expression via human adult mesenchymal stem cells: implication for cell therapy in neurodegenerative diseases. Cell Transplant 16(1):41–55
Qu Y et al (2019) Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases. Neural Regen Res 14(6):931
Rafii MS et al (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement 10(5):571–581
Raikwar SP et al (2019) Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer’s disease therapeutic target. Mol Neurobiol 56(1):378–393
MS Rao, A Khanna, S Shin, (2008) Stem cells for the treatment of neurological disorders. CNS Neurol Disord-Drug Targ (Former Curr Drug Targ-CNS Neurol Disord), 7(1): p. 98-109
Rapti K et al (2012) Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20(1):73–83
Redmond DE et al (2007) Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci 104(29):12175–12180
Ristow M (2004) Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82(8):510–529
Saadoun D et al (2011) Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365(22):2067–2077
Sahni JK et al (2011) Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Control Release 152(2):208–231
Sakthiswary R, Raymond AA (2012) Stem cell therapy in neurodegenerative diseases: from principles to practice. Neural Regen Res 7(23):1822
Sanooghi D et al (2021) Differentiation of mesenchymal stem cells derived from human adipose tissue into cholinergic-like cells: an in vitro study. Basic Clin Neurosci 12(3):315
Sasmita AO (2019) Current viral-mediated gene transfer research for treatment of Alzheimer’s disease. Biotechnol Genet Eng Rev 35(1):26–45
Stamatovic SM, Keep RF, Andjelkovic AV (2008) Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol 6(3):179–192
Takagi Y et al (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Investig 115(1):102–109
Tong BC-K et al (1865) (2018) Calcium signaling in Alzheimer’s disease & therapies. Biochimica Et Biophysica Acta (BBA)-Mol Cell Res. 11:1745
Venkatas J, Singh M (2021) Nanomedicine-mediated optimization of immunotherapeutic approaches in cervical cancer. Nanomedicine 16(15):1311–1328
Wang M-M et al (2018) Innate immune activation in Alzheimer’s disease. Ann Trans Med 6(10):1
Watabe K et al (2000) Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res 60(4):511–519
Xu L et al (2006) Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 82(7):865–875
Yang JA et al (2014) α-Synuclein’s adsorption, conformation, and orientation on cationic gold nanoparticle surfaces seeds global conformation change. J Phys Chem B 118(13):3559–3571
Yaqoob SB et al (2020) Gold, silver, and palladium nanoparticles: a chemical tool for biomedical applications. Front Chem 8:376
Yasuhara T et al (2006) Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci 26(48):12497–12511
Yi L et al (2014) A non-invasive, rapid method to genotype late-onset Alzheimer’s disease-related apolipoprotein E gene polymorphisms. Neural Regen Res 9(1):69
Yin H et al (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15(8):541–555
Zhang N et al (2018) Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson’s disease therapy. Theranostics 8(8):2264
Zhao L et al (2016) Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer’s disease mouse models. Neurobiol Aging 44:159–172
Kabanov A, Gendelman HE (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders." Progress in Polymer Science 32(8–9):1054–1082
Lunn JS, Sakowski SA, Hur J, Feldman EL (2011) Stem cell technology for neurodegenerative diseases. Annu Neurol 70(3):353–361
Acknowledgements
We thank the Department of Biology, Science and Research Branch of Islamic Azad University, and the Cellular and Molecular Research Center of Iran University of medical science for their Support.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
NA, NA And SA had the original idea, wrote initial topics and headlines and the first draft. GhL, SN, BD, LM, and PM participated in the writing, editing, and final revising of the manuscript. VS, MJ, and MD supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ashraf, S.S., Hosseinpour Sarmadi, V., Larijani, G. et al. Regenerative medicine improve neurodegenerative diseases. Cell Tissue Bank 24, 639–650 (2023). https://doi.org/10.1007/s10561-022-10062-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-022-10062-0